KARD Kardigan, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2123613 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets11.8%
Debt / equity0.00x
Current ratio10.62x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $0 | — | — | — | — | — |
| R&D expense | $64.36M | $56.37M | — | $49.14M | $35.84M | — |
| SG&A expense | $22.25M | $18.87M | — | $9.94M | $21.29M | — |
| Operating income | -$64.81M | -$118.76M | — | -$59.07M | -$57.12M | — |
| Pretax income | -$58.57M | -$116.24M | — | -$60.16M | -$57.45M | — |
| Income tax | $0 | $0 | — | $0 | $0 | — |
| Net income | -$58.57M | -$116.24M | -$56.07M | -$60.16M | -$57.45M | -$18.02M |
| EBITDA | -$64.31M | -$118.36M | — | -$58.87M | -$57.02M | — |
| EPS (basic) | -0.64 | -4.61 | — | -4.43 | -4.64 | — |
| EPS (diluted) | -0.64 | -4.61 | — | -4.43 | -4.64 | — |
| Weighted avg. shares (diluted) | 92.07M | 25.20M | — | 13.57M | 12.38M | — |
| Balance sheet | ||||||
| Cash & equivalents | $78.89M | $384.00M | — | $169.50M | $90.12M | — |
| Short-term investments | $392.88M | $213.59M | — | — | — | — |
| Current assets | $484.46M | $610.16M | — | — | — | — |
| PP&E, net | $7.30M | $7.57M | — | — | — | — |
| Intangibles | $26.61M | $26.42M | — | — | — | — |
| Total assets | $649.25M | $721.79M | — | — | — | — |
| Current liabilities | $45.62M | $70.00M | — | — | — | — |
| Total liabilities | $76.73M | $106.26M | — | — | — | — |
| Shareholders' equity | $572.52M | $615.52M | -$300.63M | -$199.33M | -$151.31M | -$98.28M |
| Shares outstanding | 93.55M | 93.47M | — | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$59.85M | — | — | -$46.57M | — | — |
| Capital expenditure | $516,000 | — | — | $1.36M | — | — |
| Free cash flow | -$60.37M | — | — | -$47.93M | — | — |
| Investing cash flow | -$241.87M | — | — | -$116.95M | — | — |
| Financing cash flow | -$3.40M | — | — | $242.91M | — | — |
| Depreciation & amortization | $500,000 | $400,000 | — | $200,000 | $100,000 | — |
| Stock-based compensation | $16.98M | $11.70M | — | $3.96M | $18.65M | — |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.